SP001 Cell Therapy and Cell Choices in the Swiss Transplantation Program-From the

Size: px
Start display at page:

Download "SP001 Cell Therapy and Cell Choices in the Swiss Transplantation Program-From the"

Transcription

1 SUNDAY 14 MAY, Opening and Keynote Chair: Matthieu Stettler SP001 Cell Therapy and Cell Choices in the Swiss Transplantation Program-From the laboratory to clinical research and use Lee Ann Laurent-Applegate Topic 2: Cell engineering and analytics Chairs: Anne Tolstrup, Christopher Sellick SP002 Engineering cell metabolism to enhance protein production Nathan Lewis OR001 CRISPR-CAS BASED SYNTHETIC TRANSCRIPTION FACTORS: A STRATEGY FOR IMPROVING BIOPRODUCTION IN CHO CELLS / S. N. S. Sou* (GB) - D.-J. Kleinjan - C. Wardrope - S. Rosser OR002 DEGRADATION OF RECOMBINANT PROTEINS OF DIVERSE FORMATS BY CHO HOST CELL PROTEASES IS CIRCUMVENTED VIA KNOCK-OUT OF CHO MATRIPTASE / H. Laux* (CH) - S. Romand - U. Bodendorf OR003 TRANSPOSON-MEDIATED GENE INTEGRATION THE FUTURE OF STABLE CHO CELL LINE DEVELOPMENT? / G. Barnard* (US)

2 MONDAY 15 MAY, Topic 2: Cell engineering and analytics (continued) Chairs: Alan Dickson, Anne Tolstrup SP003 Population Dynamics of Monoclonal CHO Cell Lines Karin Anderson OR004 SMALL RNA - BIG IMPACT: USING MICRORNAS TO ENHANCE MANUFACTURABILITY OF DIFFICULT-TO-EXPRESS PROTEINS IN CHO CELLS / M. Gamer* (DE) - S. Fischer - L. Pieper - J. Fieder - P. Schulz - H. Bradl - I. Gorr SP004 Mammalian Cell Line Development, Miniaturization, Automation, and Analysis using the Berkeley Lights Platform / K. Le (US) OR006 A NOVEL SITE-SPECIFIC INTEGRATION SYSTEM FOR CELL LINE DEVELOPMENT M. C. Inniss* (US) - L. Zhang PO266 IDENTIFYING OPPORTUNITIES IN CELL ENGINEERING FOR THE PRODUCTION OF DIFFICULT TO EXPRESS RECOMBINANT PROTEINS / H. Hussain* (GB) - D. Fisher - R. Roth - A. J. Dickson PO234 OPTIMIZATION OF THE CLC FOR MANUFACTURING PURPOSES USING A NOVEL SINGLE CELL PRINTING TECHNOLOGY / A. Mahé* (CH) - P.-A. Cayatte - A. Lecomte - K. Wilson - A. Haines PO236 A NOVEL SIRNA AIDED METHOD FOR CHO CELL LINE SELECTION / A. B. Diendorfer* (AT) - V. Jadhav - Z. Wurz - F. Doyle - T. Eveleth - S. Tenenbaum - N. Borth PO308 EVALUATION OF MICRORNA-BASED GENETIC SWITCHES AS TRANSGENE EXPRESSION MODULATORS IN CHO CELLS / R. Valdés-Bango Curell* (IE) - C. Monger - K. Motheramgari - J. Meiller - A. Costello - N. Borth - M. Clynes - C. Clarke - N. Barron Topic 2: Cell engineering and analytics (continued) Chairs: Terry Papoutsakis, Alan Dickson OR007 DIRECTED EVOLUTION OF CHO CELLS WITH INCREASED SYNTHETIC CAPACITY D. James* (GB) - K. Syddall - A. Fernandez-Martell OR008 VITAMIN B5 TRANSPORT AS A METABOLIC SELECTION FOR HIGHLY EFFICIENT RECOMBINANT PROTEIN EXPRESSION BY MAMMALIAN CELLS / L. Pourcel* (CH) - V. Le Fourn - P.-A. Girod - N. Mermod OR009 GLYCOENGINEERING IN A HUMAN CELL LINE FOR IMPROVEMENT OF BIOPHARMACEUTICALS HALF LIFE / K. Nawrath* (DE) OR010 LIPIDOMICS FOR ROBUST HIGH PERFORMANCE PROCESS DEVELOPMENT / A. Mc Cann - G. Mathy* (BE) - L. Malphettes Topic 4: Cell culture based vaccines Chairs: Paula Alves, Rino Rappuoli

3 SP005 The Per.C6 cell line: From a promising vaccine manufacturing platform to proven real world performance Dirk Redlich OR011 A CONTINUOUS TUBULAR BIOREACTOR FOR STABLE PRODUCTION OF CELL CULTURE-DERIVED INFLUENZA VIRUS VACCINES / F. Tapia* (DE) - Y. Genzel - V. Sandig - U. Reichl OR012 PRODUCTION AND PURIFICATION OF ZIKA AND YELLOW FEVER VIRUS-LIKE PARTICLES (VLPS) EXPRESSED IN MAMMALIAN CELLS / L. Castilho* (BR) - R. Alvim - M. Pinho - T. Pato - A. Creanga - S.-Y. Ko - W.-P. Kong - B. Graham OR013 OPTIMIZATION OF A BIOPROCESS FOR THE DEVELOPMENT OF A WHOLE VIRUS INACTIVATED HEPATITIS C VIRUS VACCINE / A. F. Pihl* (DK) - C. K. Mathiesen - T. B. Jensen - G. P. Alzua - A. Offersgaard - U. Fahnøe - J. P. Christensen - J. Bukh - J. M. Gottwein PO221 VAXARRAY SEASONAL INFLUENZA ASSESSMENT OF CELL-DERIVED INFLUENZA VACCINE POTENCY / R. Nash* (US) - K. Rowlen - E. Dawson - L. Kuck PO166 ON-LINE MONITORING OF DIELECTRIC CELL PROPERTIES FOR THE ANALYSIS OF VIRUS-LIKE PARTICLE PRODUCTION BY CAP CELLS / S. Gutiérrez* (ES) - K. Hein - N. Civit - F. Gòdia Topic 1: Enabling cell based technologies Chairs: Michael Betenbaugh, Martin Fussenegger SP006 Solving the environmental issues for cells: Towards precise regulation of stem cell functions Ken-Ichiro Kamei OR014 A NOVEL IN VITRO PANCREATIC ISLET MODEL SYSTEM FOR DIABETES RESEARCH / A. Neelakandhan - A. Biernath - O. Frey - B. Yesildag* (CH) PO354 DEVELOPMENT OF A WOUND HEALING ASSAY USING INCLUSION BODIES / A. Stamm* (DE) - S. Strauß - P. Vogt - T. Scheper - I. Pepelanova PO363 3D-PRINTED MICROFLUIDIC CHANNEL AND CULTIVATION MOLD FOR QUANTITATIVE EVALUATION OF CELL MIGRATION PROPERTY / K.-I. Miyamoto* (JP) - T. Wagner - M. Schöning - T. Yoshinobu PO369 FLUORESCENT CELL-BASED BIOSENSORS FOR DETECTION AND QUANTIFICATION OF LABEL-FREE VIRUS AND VIRAL VECTORS / M. R. Guerreiro* (PT) - P. M. Alves - A. S. Coroadinha

4 TUESDAY 16 MAY, Topic 1: Enabling cell based technologies (continued) Chairs: Michael Betenbaugh, Martin Fussenegger SP006 Human stem cell based in vitro modeling of Parkinson s disease. Jens Schwamborn OR015 DYNAMIC REMODELING OF NEURAL CELLULAR AND EXTRACELLULAR SIGNATURES DEPICTED IN 3D IN VITRO DIFFERENTIATION OF HUMAN IPSC-DERIVED NSC / D. Simão* (PT) - A. P. Terrasso - M. M. Silva - F. Arez - M. F. Sousa - N. Raimundo - P. Gomes-Alves - E. J. Kremer - P. Alves - C. Brito OR016 MIMICKING METABOLIC LIVER ZONATION RESTORES FUNCTIONAL HETEROGENEITY IN CULTURED HEPATOCYTES / T. Wahlicht* (DE) - C. Lipps - D. Wirth TBA OR018 TRANSLATIONAL APPLICATIONS OF ORGANS-ON-A-CHIP TECHNOLOGIES / M. Cirit* (US) PO366 DEVELOPMENT OF ALTERNATIVE ANIMAL CELL TECHNOLOGY PLATFORMS: CHO BASED CELL-FREE PROTEIN SYNTHESIS SYSTEMS FOR THE PRODUCTION OF DIFFICULT-TO-EXPRESS PROTEINS / L. Thoring* (DE) - S. Dondapati - M. Stech - D. Wüstenhagen - S. Kubick PO371 AUTOMATION-COMPATIBLE MICROFLUIDIC SYSTEM FOR MULTI-TISSUE INTEGRATION / O. Frey* (CH) - D. Fluri - J.-Y. Kim - K. Renggli - A. Hierlemann - J. Kelm Topic 3: Cell culture based process engineering and product quality Chairs: Chetan Goudar, Paulo Fernandes SP008 Title TBA Thomas Ryll OR019 USE OF BIOCAPACITANCE PROBES FOR OPTIMIZED PROCESS CONTROL AT LARGE-SCALE MANUFACTURING / C. Bro* (DK) - C. Kwiatkowski - J. Goldstein - E. Schaefer - A. Tolstrup OR020 HIGH THROUGHPUT ANALYSIS OF ANTIBODY GLYCOSYLATION IN CELL CULTURE SAMPLES / S. Giehring* (DE) - C. Wosnitza - C. Meissner PO128 SEED TRAIN CULTURE CONDITIONS CAN AFFECT PRODUCTION CULTURE PERFORMANCE: A CASE STUDY FOR A CHO CELL CULTURE PROCESS / M. Gawlitzek* (US) - M. Tung - S.-H. Wang - S. Misaghi - R. Kiss PO059 DIAMINE OXIDASE N-GLYCOSYLATION SITE ASN110 IS HIGHLY CONSERVED IN EVOLUTION AND ESSENTIAL FOR SECRETION / E. Gludovacz* (AT) - D. Maresch - C. Grünwald-Gruber - V. Puxbaum - L. J. Baier - L. Lopes de Carvalho - F. Altmann - T. A. Salminen - B. Ulm - S. Pils - T. Boehm - B. Jilma - N. Borth PO145 LEACHABLES FROM SINGLE-USE DISPOSABLE BIOREACTORS MAKING BETTER BAGS WORSE / P. S. Kelly* (IE) - S. Pare - N. Barron - O. Coleman - P. Meleady - M. Clynes - S. McSweeney - J. Bones - S. Carillo - N. Dorival Garcia

5 PO174 USE OF AN ANTIOXIDANT TO IMPROVE MONOCLONAL ANTIBODY PRODUCTION AND QUALITY IN CHO CELLS / T. K. Ha* (DK) - H. F. Kildegaard - G. M. Lee PO030 INTEGRATED MEDIA BLENDING INCREASES EFFICIENCY OF CLONE SELECTION / C. Desmurget* (CH) - J.-M. Bielser - M. Jordan - D. Brühlmann - M. Nater - J. Souquet - H. Broly PO065 DEVELOPMENT OF AN ANALYTICAL APPROACH FOR ON-LINE MONITORING AND CONTROL OF MONOCLONAL ANTIBODIES QUALITY / F. Cambay* (CA) - G. De Crescenzo - O. Henry - Y. Durocher

6 WEDNESDAY 17 MAY, Topic 3: Cell culture based process engineering and product quality (continued) Chairs: Alain Bernard, Chetan Goudar SP009 Intensification of a Multi-Product Perfusion Platform through Medium and Process Development Shawn Barrett SP010 Optimization of a mammalian cell perfusion culture in productivity and product quality Moritz Wolf OR021 CONFIRMING SIALYLATION BIOMARKERS IN A CHO BIOPROCESS USING OMICS / A. Lewis* (US) - T. Erlandson - A. Lee - N. Aranibar - B. Warrack - A. Au - M. Borys - M. Reily SP011 Successes and challenges of cell culture for therapeutic mab production Thierry Ziegler Topic 3: Cell culture based process engineering and product quality (continued) Chairs: Florian Wum, Alain Bernard SP012 Another Arrow in the Quiver Cell Retention/Perfusion How, When and Why - Judicious Use of a Brute-Force Technology Gregory Hiller OR022 THE DEVELOPMENT OF NOVEL SURFACTANTS AND THEIR ROLE IN DEFINED MEDIA / T. Bus* (DE) - M. N. Leiske - A.-K. Truetzschler - E. Rudiseva - S. Klausing - C. Heinrich - A. Traeger - U. S. Schubert OR023 SMALL PROCESS CHANGES DO MATTER- MATCHING SCALE DOWN AND AT SCALE CELL CULTURE PERFORMANCE FOR A THERAPEUTIC ANTIBODY / V. Carvalhal* (US) - T. DiRocco - B. Horvath - J. Wuu - S. Meier - B. Kiss OR024 BIOCHEMICAL CHARACTERIZATION OF REDOX ACTIVE SUBSTANCES TO IMPROVE HARVEST ROBUSTNESS DURING MONOCLONAL ANTIBODY PRODUCTION / S. Loebrich* (US) - W. Chen - T. Ryll - S. Kitchener Topic 5: Emerging cell based therapeutic approaches Chairs: Nicolas Mermod, Hansjörg Hauser SP013 Title TBA Matthias Lutolf OR025 IMPROVING MATURATION OF CARDIOMYOCYTES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS: AN -OMICS DRIVEN APPROACH / C. Correia - A. Koshkin - P. Duarte - D. Hu - A. Teixeira - I. Domian - M. Serra* (PT) - P. M. Alves OR026 ASSESSMENT OF A CELL THERAPY APPROACH FOR DUCHENNE MUSCULAR DYSTROPHY USING MESOANGIOBLASTS AND TRANSPOSABLE VECTORS / P. Iyer* (CH) - L. Mavoungou - F. Ronzoni - J. Zemla - M. Jaconi - M. Lekka - N. Mermod OR027 ΒETA-CELL-MIMETIC DESIGNER CELLS PROVIDE CLOSED-LOOP GLYCEMIC CONTROL / M. Xie* (CH) - H. Ye - M. Fussenegger Keynote and closing Chair: Chetan Goudar

7 SP011 Technologies Tailored for Cellular Therapy Manufacturing Jamie Piret

SCIENTIFIC PROGRAMME CELL THERAPY AND CELL CHOICES IN THE SWISS TRANSPLANTATION PROGRAM- FROM THE LABORATORY TO CLINICAL RESEARCH AND USE

SCIENTIFIC PROGRAMME CELL THERAPY AND CELL CHOICES IN THE SWISS TRANSPLANTATION PROGRAM- FROM THE LABORATORY TO CLINICAL RESEARCH AND USE 34 CELL THERAPY AND CELL CHOICES IN THE SWISS TRANSPLANTATION PROGRAM- FROM THE LABORATORY TO CLINICAL RESEARCH AND USE ENGINEERING CELL METABOLISM TO ENHANCE PROTEIN PRODUCTION CRISPR-CAS BASED SYNTHETIC

More information

Course Agenda. Day One

Course Agenda. Day One Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

More information

Wednesday, August 17, Mini-Review (2016) in Applied Microbiology and Biotechnology

Wednesday, August 17, Mini-Review (2016) in Applied Microbiology and Biotechnology Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production Wednesday, Mini-Review () in Applied Microbiology

More information

CELL TECHNOLOGIES FOR INNOVATIVE THERAPIES PROGRAMME BOOK

CELL TECHNOLOGIES FOR INNOVATIVE THERAPIES PROGRAMME BOOK CELL TECHNOLOGIES FOR INNOVATIVE THERAPIES PROGRAMME BOOK 3 CONTENTS CONTENTS WELCOME LETTERS.............................................................5 COMMITTEES..................................................................7

More information

M e t h o d s in Molecular Biology

M e t h o d s in Molecular Biology M e t h o d s in Molecular Biology Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651

More information

Future Perspectives of Antibody Manufacturing

Future Perspectives of Antibody Manufacturing BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast

More information

Advanced Microbial Protein Expression

Advanced Microbial Protein Expression Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality

More information

Manufacturing and Characterization Challenges for Human Stem Cell Products

Manufacturing and Characterization Challenges for Human Stem Cell Products Manufacturing and Characterization Challenges for Human Stem Cell Products Center for Biomedicine and Genetics Beckman Research Institute of City of Hope Larry A. Couture, Ph.D January, 2009 Center for

More information

Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY CHANDIGARH

Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY CHANDIGARH Thursday 5 November EU-India PARTNERING EVENT Theme: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes IMTECH Debendra K. Sahoo INSTITUTE OF MICROBIAL TECHNOLOGY

More information

Molecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics

Molecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics Molecular Medicine Molecular Medicine Stem cell therapy Gene therapy Tumor therapy Immunotherapy Other therapies Vaccines Genetic diagnostics Medical genomics Medication Diagnostics medicine: old desire

More information

Kupers Luc IMI webinar

Kupers Luc IMI webinar Biomanufacturing 2020 (biomfg2020): Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes Kupers

More information

Subject Index. chromatography step, 125-

Subject Index. chromatography step, 125- A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade

More information

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams,

More information

Subject Index. See for options on how to legitimately share published articles.

Subject Index. See   for options on how to legitimately share published articles. Downloaded via 148.251.232.83 on March 27, 2019 at 03:59:27 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. A Alert limits, description, 70

More information

LFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING

LFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING COMMITMENT AND FLEXIBILITY LFB BIOMANUFACTURING is a medium-sized CDMO offering Bioproduction services, from an industrial facility

More information

sirna Overview and Technical Tips

sirna Overview and Technical Tips 1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION

More information

Synthetic vaccine research and development. Comprehensive and innovative synthetic biology solutions and technologies

Synthetic vaccine research and development. Comprehensive and innovative synthetic biology solutions and technologies Synthetic vaccine research and development Comprehensive and innovative synthetic biology solutions and technologies From plan to product, Thermo Fisher Scientific supports your synthetic vaccine goals

More information

Evolving of Biological Product Expression Systems with Host Cell Engineering

Evolving of Biological Product Expression Systems with Host Cell Engineering Evolving of Biological Product Expression Systems with ost Cell Engineering Lianchun Fan Bristol-Myers Squibb CMC Strategy Forum Jan. 23rd, 2017 Outline Choice of expression systems New technologies and

More information

Upstream mammalian cell processing challenges and prospects

Upstream mammalian cell processing challenges and prospects BioProcess International Berlin, April 11-14, 2005 Upstream mammalian cell processing challenges and prospects John Birch Lonza Significance of Mammalian Cell Processes Commercial significance of biopharmaceutical

More information

Stem Cell Services. Driving Innovation for Stem Cell Researchers

Stem Cell Services. Driving Innovation for Stem Cell Researchers Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,

More information

Utility of Branched DNA Hybridization Methodology for the Quantitation of Oligonucleotides

Utility of Branched DNA Hybridization Methodology for the Quantitation of Oligonucleotides Utility of Branched DNA Hybridization Methodology for the Quantitation of Oligonucleotides Laboratory Sciences, MPI Research, A Charles River Company Amy Smith, BA, Senior Director, Bioanalytical/Analytical

More information

Des cellules-souches dans le poumon : pourquoi faire?

Des cellules-souches dans le poumon : pourquoi faire? Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland

More information

Polaris and Callisto: Advances in Cellular Biology. Jordan Moore Senior Field Applications Specialist

Polaris and Callisto: Advances in Cellular Biology. Jordan Moore Senior Field Applications Specialist Polaris and Callisto: Advances in Cellular Biology Jordan Moore Senior Field Applications Specialist Single-Cell Biology Number of cells The population average is a lie average Transcripts per cell Gene

More information

Relative cost of hepatocytes

Relative cost of hepatocytes Relative cost of hepatocytes - WORKPACKAGE 8 PROGENITOR CELLS FOR BIO- ARTIFICIAL LIVER UNEW, Charité, SCS StemCellSystems WP2 System design and medical device regulatory requirements WP7 Communications,

More information

A Survey of Genetic Methods

A Survey of Genetic Methods IBS 8102 Cell, Molecular, and Developmental Biology A Survey of Genetic Methods January 24, 2008 DNA RNA Hybridization ** * radioactive probe reverse transcriptase polymerase chain reaction RT PCR DNA

More information

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) ANNOUNCEMENTS HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) Lectures 6 8 Outline Stem Cell Division - symmetric - asymmetric Stem cell lineage potential - pluripotent

More information

ANNOUNCEMENTS. HW1 is due Thursday 1/28 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) Wednesday 9:45 10:15 (ECCH 134)

ANNOUNCEMENTS. HW1 is due Thursday 1/28 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) Wednesday 9:45 10:15 (ECCH 134) ANNOUNCEMENTS HW1 is due Thursday 1/28 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) Wednesday 9:45 10:15 (ECCH 134) Lecture 5: Kinetics of Cell Growth in Culture Phenomenological mathematical

More information

Versatility and performance of Lipofectamine Stem Transfection Reagent

Versatility and performance of Lipofectamine Stem Transfection Reagent PPLICTION NOTE Stem Transfection Reagent Versatility and performance of Stem Transfection Reagent Introduction The ability of stem cells to self-renew and differentiate into various specialized cell types

More information

The World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.

The World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc. The World Leader in SPR Technology Jimmy Page, PhD, Biacore, Inc. Objectives of Biacore Experiments Yes/No Data» Is there binding?» Ligand Fishing Concentration Analysis: How MUCH? Active Concentration

More information

Synthetic Biology. Sustainable Energy. Therapeutics Industrial Enzymes. Agriculture. Accelerating Discoveries, Expanding Possibilities. Design.

Synthetic Biology. Sustainable Energy. Therapeutics Industrial Enzymes. Agriculture. Accelerating Discoveries, Expanding Possibilities. Design. Synthetic Biology Accelerating Discoveries, Expanding Possibilities Sustainable Energy Therapeutics Industrial Enzymes Agriculture Design Build Generate Solutions to Advance Synthetic Biology Research

More information

Gene and Cell Therapy. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0

Gene and Cell Therapy. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0 2018/2019 Gene and Cell Therapy Code: 101920 ECTS Credits: 6 Degree Type Year Semester 2501230 Biomedical Sciences OT 4 0 Contact Name: Maria Fátima Bosch Tubert Email: Fatima.Bosch@uab.cat Teachers Use

More information

MiniTEM. Designed for nanoparticle characterization

MiniTEM. Designed for nanoparticle characterization MiniTEM Designed for nanoparticle characterization MiniTEM revolutionizes access to transmission Transmission electron microscopy (TEM) is unmatched in providing high resolution images that allow visual

More information

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy April 24, 2017 Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics,

More information

Potelligent CHOK1SV. How It Works. Potelligent CHOK1SV

Potelligent CHOK1SV. How It Works. Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV How It Works A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and

More information

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams,

More information

The Elite Provider. Cell & Gene. Therapy Manufacturing

The Elite Provider. Cell & Gene. Therapy Manufacturing The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists

More information

Cell and gene therapy: scaling up and moving to mass production

Cell and gene therapy: scaling up and moving to mass production EDITORIAL Cell and gene therapy: scaling up and moving to mass production Nigel Whittle In order to fulfil the promise of cell therapy, it is important that manufacture of these therapies can be industrialized

More information

System Biology and Immune Response

System Biology and Immune Response System Biology and Immune Response Fondation Mérieux Conference Centre Les Pensières Veyrier-du-Lac - France June 21-23, 2010 Steering Committee: Nicolas BURDIN Bruno GUY Michael KATZE Jacques LOUIS Ray

More information

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare

More information

Maximizing the Potential of Biomanufacturing Cell Lines

Maximizing the Potential of Biomanufacturing Cell Lines Maximizing the Potential of Biomanufacturing Cell Lines Contents Introduction... 3 CHO cells The key trends... 3 The increasing popularity... 3 The biological context... 4 Batch size/price... 4 Novel antibody

More information

NaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER

NaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER Nanoplasmid TM Platform NaNoplasmid TM The Nanoplasmid is a dramatically improved Key Cassette (

More information

The Cell and Gene Therapy Catapult UK clinical trials database

The Cell and Gene Therapy Catapult UK clinical trials database The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)

More information

LIVER FIBROSIS; NOVEL FINDINGS ABOUT THE MECHANISM OF EXCESSIVE COLLAGEN SYNTHESIS

LIVER FIBROSIS; NOVEL FINDINGS ABOUT THE MECHANISM OF EXCESSIVE COLLAGEN SYNTHESIS LIVER FIBROSIS; NOVEL FINDINGS ABOUT THE MECHANISM OF EXCESSIVE COLLAGEN SYNTHESIS BRANKO STEFANOVIC COM FSU GRAND ROUNDS 2009 PREVALENCE OF LIVER FIBROSIS IN USA 1 IN 679 PEOPLE; 400,000 PEOPLE IN USA

More information

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA FDA Update Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA 13 th Annual FDA and the Changing Paradigm for HCT/P Regulation February 13, 2017

More information

Introduction of Development Center for Biotechnology TAIWAN

Introduction of Development Center for Biotechnology TAIWAN Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394

More information

SPO GRANTS (2001) PHASES

SPO GRANTS (2001) PHASES 2002 SPO GRANTS (2001) PHASES MAIN PHASES Legal organisation of the Institute of Biotechnology Ankara University Biotechnology Labs Organisation of Central Lab of the Institute of Biotechnology/ Purchase

More information

ibio, Inc. Holds Annual Meeting in College Station, Texas

ibio, Inc. Holds Annual Meeting in College Station, Texas April 7, 2016 ibio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY -- (Marketwired) -- 04/07/16 -- ibio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the ibio, Inc. (NYSE MKT:

More information

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com

More information

CONTRACTING CELL CULTURE

CONTRACTING CELL CULTURE CONTRACTING CELL CULTURE BIOTECH EXPERIENCE Page 2 Professionals in proteins and antibodies Bayer HealthCare has more than 130 years of experience in developing and producing pharmaceuticals. An integral

More information

Genetics and Genomics in Medicine Chapter 9 Questions

Genetics and Genomics in Medicine Chapter 9 Questions Genetics and Genomics in Medicine Chapter 9 Questions Multiple Choice Questions Question 9.1 Which, if any, of the following can be classified as a type of augmentation therapy? a) Treatment using a small

More information

Lectures 28 and 29 applications of recombinant technology I. Manipulate gene of interest

Lectures 28 and 29 applications of recombinant technology I. Manipulate gene of interest Lectures 28 and 29 applications of recombinant technology I. Manipulate gene of interest C A. site-directed mutagenesis A C A T A DNA B. in vitro mutagenesis by PCR T A 1. anneal primer 1 C A 1. fill in

More information

How Targets Are Chosen. Chris Wayman 12 th April 2012

How Targets Are Chosen. Chris Wayman 12 th April 2012 How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench

More information

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic

More information

NIH-RAID: A ROADMAP Program

NIH-RAID: A ROADMAP Program NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the

More information

Expressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes

Expressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes Expressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes Genes can be regulated at many levels Usually, gene regulation, are referring to transcriptional

More information

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University Issues in production of viral gene transfer vectors Stefan Kochanek Department of Gene Therapy Ulm University Only few positive results in gene therapy so far - many early phase, few late phase clinical

More information

Scale-Up and Manufacturing of Cell-Based Therapies III

Scale-Up and Manufacturing of Cell-Based Therapies III Preliminary Program Scale-Up and Manufacturing of Cell-Based Therapies III January 5 9, 2014 San Diego, CA, USA Conference Chair: Chris Mason University College London Greg Russotti Celgene Cellular Therapeutics

More information

BIOTECHNOLOGY. Course Syllabus. Section A: Engineering Mathematics. Subject Code: BT. Course Structure. Engineering Mathematics. General Biotechnology

BIOTECHNOLOGY. Course Syllabus. Section A: Engineering Mathematics. Subject Code: BT. Course Structure. Engineering Mathematics. General Biotechnology BIOTECHNOLOGY Subject Code: BT Course Structure Sections/Units Section A Section B Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Unit 7 Section C Section D Section E Topics Engineering Mathematics General

More information

Mayo Clinic Arizona/Rochester and U. Minnesota

Mayo Clinic Arizona/Rochester and U. Minnesota Mayo Clinic Arizona/Rochester and U. Minnesota Overcoming Drug Resistance in Multiple Myeloma Project 1: Develop high throughput drug screening platform for myeloma cell lines and >500 primary patient

More information

Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production

Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production May/June 2013 1 The world leader in serving science Agenda

More information

Conference Calendar. healthtech.com. January High-Content Analysis January 8-11 San Francisco, CA

Conference Calendar. healthtech.com. January High-Content Analysis January 8-11 San Francisco, CA High-Content Analysis January 8-11 San Francisco, CA www.highcontentanalysis.com January 2013 PepTalk January 21-25 Palm Springs, CA www.chi-peptalk.com January 24-25 Pipeline 1: Formulation: Optimizing

More information

Biotechnology: Genomics: field that compares the entire DNA content of different organisms

Biotechnology: Genomics: field that compares the entire DNA content of different organisms Biotechnology: New Terms Today: Genome Genetic engineering, transgenic organisms, GM food, Reproductive and therapeutic cloning Stem cells, plouripotent, totipotent Gene therapy Genomics: field that compares

More information

IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY

IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY IMPORTANCE OF CELL CULTURE MEDIA TO THE BIOPHARMACEUTICAL INDUSTRY Research, development and production of biopharmaceuticals is growing rapidly, thanks to the increase of novel therapeutics and biosimilar

More information

Dr: RAWIA BADR Associate Professor of Microbiology&Immunology

Dr: RAWIA BADR Associate Professor of Microbiology&Immunology Dr: RAWIA BADR Associate Professor of Microbiology&Immunology Cell culture Commonly refers to the culture of animal cells and tissues, while the more specific term plant tissue.culture is used only for

More information

Expression of Next Generation Biologics Requires Next Generation Expression Systems

Expression of Next Generation Biologics Requires Next Generation Expression Systems Expression of Next Generation Biologics Requires Next Generation Expression Systems Joachim Klein, Ph.D., Associate Director, Head of Strain Development and Cell Banking Georg Blaser, Ph.D., Associate

More information

Partnering for Impact Human Health Therapeutics

Partnering for Impact Human Health Therapeutics Partnering for Impact Human Health Therapeutics Bernard Massie General Manager Human Health Therapeutics Partnering for Impact in Biologics and Vaccines NRC s Human Health Therapeutics (HHT) portfolio

More information

Pluripotent Stem Cells for Drug Development and Therapy: Bioprocess Challenges

Pluripotent Stem Cells for Drug Development and Therapy: Bioprocess Challenges Pluripotent Stem Cells for Drug Development and Therapy: Bioprocess Challenges Paula Alves Animal Cell Technology Unit ibet Instituto de Biologia Experimental e Tecnológica www.ibet.pt Human Stem Cells

More information

Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy

Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy Chao Liang 1,2, Baosheng Guo 1, Heng Wu 1, Lingqiang Zhang 2, Aiping

More information

The NYSCF Research Institute

The NYSCF Research Institute Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human

More information

Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies

Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930

More information

Stem Cells: Introduction and Prospects in Regenerative Medicine.

Stem Cells: Introduction and Prospects in Regenerative Medicine. Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,

More information

Protein Sources (Heterologous expression of proteins)

Protein Sources (Heterologous expression of proteins) Protein Sources (Heterologous expression of proteins) Adrian Suarez Covarrubias Before starting out - why? what? when? where? Recombinant expression? if so, choice of host: prokaryote? eukaryote? modification

More information

Personalized CAR-T Immunotherapy Platform

Personalized CAR-T Immunotherapy Platform GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom

More information

hpsc Growth Medium DXF Dr. Lorna Whyte

hpsc Growth Medium DXF Dr. Lorna Whyte hpsc Growth Medium DXF Dr. Lorna Whyte 27.06.2014 Training from Heidelberg Overview Background: Stem Cells Introduction: Human Pluripotent Stem Cells (hpsc) vs. Adult Stem Cells Promise of PSC Research

More information

Calvin College Biosafety Application

Calvin College Biosafety Application SECTION 1: GENERAL INFORMATION Calvin College Biosafety Application Applicant Name: Campus Address: Email Address: Campus Phone #: Project Title: APPLICATION TYPE: Research Teaching Course #(s) PROTOCOL

More information

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing

More information

1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing

More information

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells

More information

Chapter 8 Healthcare Biotechnology

Chapter 8 Healthcare Biotechnology Chapter 8 Healthcare Biotechnology Outline: 8.1 Introduction 8.2 Biopharming 8.3 Models of Human Disease 8.4 Detecting and Diagnosing Human Disease 8.5 Monoclonal Antibodies 8.6 Gene Therapy 8.7 Tissue

More information

Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics

Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics Kristina Lae, Scientist, Cell Culture Cobra Biologics, Södertälje, Sweden Cobra Biologics and

More information

IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT

IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT TIA BUSH VICE PRESIDENT, SITE OPERATIONS SERVING PATIENTS IS A PRIVILEGE 2 THIS PRIVILEGE COMES WITH SIGNIFICANT RESPONSIBILITIES

More information

Outline. Upstream Processing: Development & Optimization

Outline. Upstream Processing: Development & Optimization Upstream Processing: Development & Optimization Kamal Rashid, Ph.D., Director Biomanufacturing Education & Training Center Worcester Polytechnic Institute Outline Introduction to Upstream processing Microbial

More information

QPCR in Biopharmaceuticals & Current Issues. Chaminda Salgado Head of PCR Services

QPCR in Biopharmaceuticals & Current Issues. Chaminda Salgado Head of PCR Services QPCR in Biopharmaceuticals & Current Issues Chaminda Salgado Head of PCR Services Summary Biopharm lifecycle Candidate Plasmid Selection Cell Line Selection Cell Banking Process Support Potency/Stability

More information

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research.

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research. Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research. by Altogen Labs, 11200 Manchaca Road, Suite 203 Austin TX 78748 USA Tel. (512) 433-6177

More information

OmicsLink shrna Clones guaranteed knockdown even in difficult-to-transfect cells

OmicsLink shrna Clones guaranteed knockdown even in difficult-to-transfect cells OmicsLink shrna Clones guaranteed knockdown even in difficult-to-transfect cells OmicsLink shrna clone collections consist of lentiviral, and other mammalian expression vector based small hairpin RNA (shrna)

More information

MAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES. I. Knezevic, R. Sheets Feb, 2018 Geneva, Switzerland

MAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES. I. Knezevic, R. Sheets Feb, 2018 Geneva, Switzerland MAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES I. Knezevic, R. Sheets 21-23 Feb, 2018 Geneva, Switzerland CONTEXT OF DISCUSSION WHO Consultation held to determine whether the

More information

Biotechnology: Quality Assurance and Validation

Biotechnology: Quality Assurance and Validation r Biotechnology: Quality Assurance and Validation Drug Manufacturing Technology Series Volume 4 Kenneth E. Avis Carmen M. Wagner Vincent L. Wu Editors Interpharm Press, Inc. Buffalo Grove, Illinois CONTENTS

More information

Allen Chen, Yu Ming Lim, Shaul Reuveny and Steve Oh

Allen Chen, Yu Ming Lim, Shaul Reuveny and Steve Oh EXPANSION AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO NEURAL PROGENITORS: A SIMPLIFIED BIOREACTOR PROCESS REPLACING NOGGIN WITH 2 SMALL MOLECULES Allen Chen, Yu Ming Lim, Shaul Reuveny and Steve

More information

Development from Bench to Clinic

Development from Bench to Clinic Accelerating Novel Vaccine Development from Bench to Clinic Roger Lias. Ph.D. President Eden Biodesign, Inc Questions Questions are encouraged and can be asked by sending an email to: edenbiodesign@propelmg.com

More information

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline CQAs for C&GT Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development

More information

Linker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.

Linker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p. Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements

More information

Genetics - Problem Drill 19: Dissection of Gene Function: Mutational Analysis of Model Organisms

Genetics - Problem Drill 19: Dissection of Gene Function: Mutational Analysis of Model Organisms Genetics - Problem Drill 19: Dissection of Gene Function: Mutational Analysis of Model Organisms No. 1 of 10 1. The mouse gene knockout is based on. (A) Homologous recombination (B) Site-specific recombination

More information

Considerations in Product Development with Advanced Therapies and Cancer Vaccines

Considerations in Product Development with Advanced Therapies and Cancer Vaccines Considerations in Product Development with Advanced Therapies and Cancer Vaccines Thomas Hinz Head of Section Therapeutic Vaccines Paul-Ehrlich-Institut hinth@pei.de Thomas Hinz, October 29, 2008, San

More information

LabChip GXII: Antibody Analysis

LabChip GXII: Antibody Analysis WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology

More information

HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT

HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT INTRODUCTION Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate

More information

Custom Antibodies & Recombinant Proteins

Custom Antibodies & Recombinant Proteins Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

More information

Cellular and Gene Therapy Products - CBER Update

Cellular and Gene Therapy Products - CBER Update DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTER FOR BIOLOGICS EVALUATION and RESEARCH Cellular and Gene Therapy Products - CBER Update Well Characterized Biological Products January 12-14, 2009 Kimberly

More information

Genome Editing & Engineering Conference

Genome Editing & Engineering Conference Choosing the right gene editing technology February 18-19, 2016, San Diego-CA, The Genome Editing & Engineering Congress brings together the key industry leaders and researchers to address the concepts,

More information

Cell Culture Engineering XIV

Cell Culture Engineering XIV Preliminary Program (Feb 19, 2014) Cell Culture Engineering XIV May 4-9, 2014 Fairmont Le Château Frontenac Quebec City, Canada Conference Chairs Amine Kamen McGill University, Canada Weichang Zhou Wuxi

More information